MSLN and pancreatic ductal adenocarcinoma: An early study from Carl June’s group in Pennsylvania used mRNA electroporated CAR T cells transiently expressing an anti-mesothelin scFv alongside the CD3-zeta chain and the 4-1-BB intracellular domain to treat six patients with metastatic, chemo-refractory pancreatic ductal adenocarcinoma [89].